According to filings with the U.S. Securities and Exchange Commission, Lycia Therapeutics is raising up to $106,600,004.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Aetna Trombley played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Lycia Therapeutics
We are building upon the novel platform developed by academic founder Professor Carolyn Bertozzi at Stanford University to develop LYTAC (lysosomal targeting chimera) protein degraders that harness the cells lysosomal trafficking and degradation pathway to target both soluble and membrane-bound extracellular proteins. Applications of the LYTAC platform include: targeting challenging membrane proteins, clearing pathogenic immune complexes in circulation and depleting antibodies to specific antigens of interest. The platform can potentially deliver next-generation therapeutics to address a range of difficult-to-treat diseases, including cancer and autoimmune diseases.

To learn more about Lycia Therapeutics, visit http://lyciatx.com/

Contact:
Aetna Trombley, Chief Executive Officer
650-686-8821
https://www.linkedin.com/in/aetna-wun-trombley/

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.